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This article presents methods and 
results of surgery and radiotherapy 
of brain metastases from non-small 
cell lung cancer (BMF-NSCLC). Pa-
tients with single BMF-NSCLC, with 
Karnofsky score ≥ 70 and controlled 
extracranial disease are the best 
candidates for surgery. Stereotactic 
radiosurgery (SRS) is recommended 
in patients with 1–3 BMF-NSCLC be-
low 3–3.5 cm, with minor neurologi-
cal symptoms, located in parts of the 
brain not accessible to surgery, with 
controlled extracranial disease. Whole 
brain radiotherapy (WBRT) following 
SRS reduces the risk of local relapse; 
in selected patients median surviv-
al reaches more than 10 months. 
Whole brain radiotherapy alone is 
a treatment in patients with multiple 
metastases, poor performance sta-
tus, uncontrolled extracranial disease, 
disqualified from surgery or SRS with 
median survival 3 to 6 months. There 
is no doubt that there are patients 
with BMF-NSCLC who should receive 
only the best supportive care. There is 
a debate in the literature on how to 
select these patients.
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Introduction
Lung cancer is the most common cause of brain metastases (40–50%), 
and comes before breast cancer (15–25%) and melanoma (5–15%) in this re-
spect [1–6]. In patients with non-small cell lung cancer (NSCLC), accounting 
for 80–85% of all lung cancers, the risk of development of brain metastases 
(BMF-NSCLC) throughout the course of the disease is 30–50%; brain metas-
tases are found in 7–10% of patients with NSCLC at diagnosis [7–18]. The risk 
of BMF-NSCLC development is significantly higher in patients with advanced 
NSCLC (stage III and IV) and in patients with adenocarcinoma and large-cell 
carcinoma, as compared to squamous-cell carcinoma histology [12–14, 19, 
20]. Hsiao et al., in an analysis of 482 patients with stage IIIb–IV NSCLC, 
found that the risk of brain metastasis was statistically significantly higher 
in women, patients aged less than 60 years and in patients with adenocar-
cinoma histology [7].
In over 50% of patients BMF-NSCLC occur synchronously, and in 45–50% 
of patients multiple focal lesions are found; 5–15% patients are asymptom-
atic and brain metastases are found in them on imaging studies [10, 12, 14].
Occurrence of BMF-NSCLC is associated with a very poor prognosis: me-
dian survival of untreated patients is about 1 month [1, 6, 8, 10, 11, 15, 17, 
18, 21, 22] and of those receiving palliative corticosteroid treatment slightly 
over 2 months [17, 18]. Palliative whole brain radiotherapy (WBRT) prolongs 
median survival to 3–6 months [8, 10, 17]. For many years, these extremely 
poor treatment results caused exclusion of patients with BMF-NSCLC from 
any controlled clinical studies that investigated e.g. systemic treatment. 
However, in recent years a positive change has been observed [15, 22]. In 
patients qualified for definitive surgery or stereotactic radiosurgery (SRS), 
with or without WBRT, median survival reaches even more than 10 months; 
however, this is true only for selected patients: with good performance sta-
tus, complete or very good extracranial disease control and 1–3 BMF-NSCLC 
[8, 15, 18, 23–27].
The following methods are used in the treatment of BMF-NSCLC: surgery, 
SRS, WBRT, systemic treatments (chemotherapy, immunotherapy) and vari-
ous combinations of these methods [1, 2, 4–6, 8, 9, 11, 12, 17–19, 26, 28–35]. 
In general, local (surgery, SRS) [1, 4, 6, 8, 17, 18, 28–30, 35] or regional (WBRT) 
[1, 4, 19, 28–30, 33–35] treatment is preferred, including combination of sur-
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gery and radiotherapy. There is a growing importance of 
systemic treatment, in particular of immunotherapy [1, 2, 
4, 11, 12, 30–32].
Surgery
Three controlled clinical studies have compared the ef-
ficacy of surgery combined with WBRT to that of WBRT 
alone, in patients with single brain metastasis, mainly 
from NSCLC [36–38]. The results of these studies are pre-
sented in Table 1.
In the study of Patchell et al., median survival was 
15 weeks in patients treated with radiotherapy alone and 
40 weeks in the group of patients treated with surgery; 
time to relapse or progression of brain lesions was 21 we- 
eks and 59 weeks, respectively [36]; both differences were 
highly statistically significant. The study by Vecht et al. 
has confirmed the statistically significant positive effect of 
surgery on patients’ survival, expressed as prolongation of 
median survival by 12 months [37].
In a study by Mintz et al., no improvement of survival 
of patients treated with surgery and WBRT was found, as 
compared to patients treated with WBRT alone. It should 
be stressed however that in this study, extracranial dis-
ease control was achieved in only 21% of patients, where-
as in the previous two studies this control was found in 
over 60% of patients. Additionally, patients analysed by 
Patchell et al. had a MRI scan before surgery, whereas it 
was not done in any patient from the group studied by 
Mintz, which puts into question unifocality of brain lesions 
in the latter group [36, 38].
Qualification of patients for surgical treatment of 
BMF-NSCLC is based on assessment of three basic factors: 
patient’s performance status, level of extracranial disease 
control and brain lesion status [4, 6, 30]. Patients with 
single BMF-NSCLC, with Karnofsky score (KPS) of 70 or 
more and controlled extracranial disease are the best 
candidates for surgery [4, 29]. According to Mamelak et 
al., combination of surgery and WBRT in this group of pa-
tients allows 5-year survival to be achieved in 10–20% of 
patients [4].
It is however unquestionable that the level of extracra-
nial disease control has a significant impact on the pa-
tient’s future and on the decision whether to perform sur-
gical treatment of BMF-NSCLC [23]. Analysis of the study 
of Mintz et al. clearly shows that the majority of deaths 
resulted from locoregional NSCLC progression or from dis-
tant extracranial metastasis and not from the presence of 
BMF-NSCLC themselves [38]. In general, BMF-NSCLC sur-
gery is not recommended for patients with life expectancy 
not exceeding 3 months [4, 6]. 
In some patients surgical treatment may be justified ir-
respective of the level of extracranial disease control; the 
following patients are included:
•	 patients with large (> 3 cm) tumours, causing significant 
neurological deficit and/or high intracranial hyperten-
sion (mass effect),
•	 patients with tumours located in the posterior cranial 
fossa, with a risk of secondary hydrocephalus or brain-
stem compression,
•	 patients with haemorrhagic, necrotic or cystic tumours, 
with a surrounding oedema zone.
Nowadays, presence of more than one BMF-NSCLC is 
not a contraindication for surgical treatment of brain me-
tastases; even if resection of all BMF-NSCLC is impossible, 
removal of one or more metastases that are particularly 
burdensome to the patient may be justified [6, 39–41]. 
Surgery may also be indicated in case of uncertain nature 
of brain lesions or if there is a need to determine biologi-
cal features of BMF-NSCLC that may affect selection of e.g. 
targeted therapy [4, 6, 29].
Appropriate qualification of patients for surgical treat-
ment of BMF-NSCLC ensures good tolerance and lack of 
complications. Improvement of local efficacy of BMF-NS-
CLC surgery may be expected along with progress of sur-
gical technique, including in particular en bloc resections 
and resections with clear microscopic margins [29, 42, 43].
Radiotherapy
Stereotactic radiosurgery
Stereotactic radiosurgery may be performed with three 
types of radiation: high energy photons obtained from 
linear accelerators, gamma rays from a cobalt unit (gam-
ma-knife) and relatively rarely, due to limited availability, 
with a proton beam from a cyclotron. According to pro-
tocol RTOG 90-05, the maximum tolerated single dose 
of radiation for a tumour of a diameter of 31–40 mm is 
15 Gy, of 21–30 mm – 18 Gy and below 20 mm – 24 Gy [30, 
35, 44]. Slightly lower doses are suggested for BMF-NSCLC 
located in or near the brain stem, optic nerves and optic 
chiasm [4].
Table 1. Results of controlled clinical studies comparing the efficacy of surgery combined with WBRT to that of WBRT alone
Authors, publication 
year, reference no.
% of patients with 
extracranial disease 
control
Method of treatment of 
brain metastases
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Stereotactic radiosurgery is used as:
•	 the only treatment method for selected patients with 
BMF-NSCLC,
•	 the primary treatment method, followed by WBRT,
•	 a method of local dose escalation (boost) after WBRT,
•	 a method of treatment of BMF-NSCLC relapses, after 
both WBRT and SRS (re-SRS).
The best candidates for SRS treatment are patients:
•	 with single (1–3) BMF-NSCLC, of a diameter not exceed-
ing 3–3.5 cm,
•	 with BMF-NSCLC located in all brain regions including 
those not accessible to surgery,
•	 with no or only minor neurological symptoms,
•	 with controlled extracranial disease [4, 30, 35].
Stereotactic radiosurgery efficacy in the treatment of 
BMF-NSCLC has been confirmed unequivocally in numer-
ous retrospective and prospective studies [4, 8, 17, 18, 28, 
30, 35, 44–59]. A response to SRS (decreased size of the 
metastasis or its growth inhibition) is found in 80–93% of 
patients, 1-year local control in 61–86% of patients; me-
dian survival ranges from 7 to 14 months [4, 8, 18, 35, 49, 
50]. Acute toxicity develops in 5–18% of patients undergo-
ing SRS, and includes headache, nausea, exacerbation of 
existing neurological symptoms, epilepsy; a late complica-
tion may be radiation-induced brain necrosis that is found 
in 2–6% of patients, with a clear association with SRS dose 
and with the size of the target volume [4, 35, 44].
In 2004, Hu et al. reported that in a group of patients 
with stage I NSCLC according to the AJCC, patients with 
single BMF-NSCLC had similar survival as patients with 
disease of the same stage without BMF-NSCLC, provid-
ed that an aggressive treatment (chemo-radiotherapy) of 
chest lesion and surgery or SRS of the brain metastasis 
were performed [56]. In 2008, Flannery et al. analysed 
a group of patients treated with curative intent for NSCLC, 
with a single synchronous BMF-NSCLC treated with SRS; 
median survival of patients was 18 months, and 5-year 
overall survival was 21% [57]. In 2010, Mariya et al. de-
scribed a group of 84 patients treated initially with SRS; in 
44 (52.4%) patients 1 metastasis was found, in 27 (32.1%) – 
2, in 8 (9.5%) – 3, and in 5 (6.0%) more than 4 BMF-NSCLC. 
One- and 5-year overall survival was 38% and 11%, re-
spectively, and median survival was 9 months. Fifteen 
patients survived over two years, of whom 97% (13/15) 
had 1 BMF-NSCLC at presentation, and brain metasta-
ses outside the irradiated (SRS) volume appeared only in 
3/15 (20%) patients [8]. In 2011, Marko et al. presented an 
analysis of 26 patients with asymptomatic BMF-NSCLC, 
treated with SRS alone. In this group, KPS was 90–100, 
and the mean number of brain metastases was 1.6; 
40 BMF-NSCLC were irradiated in total. Mean survival was 
12.3 ±4.3 months. The investigated group of patients was 
compared with groups of patients subject to WBRT alone 
(mean survival – 12.3 months), WBRT + SRS (mean survival 
– 12.7 months) and WBRT + surgery (mean survival – 20.2 
months), matched with respect to clinical characteristics. 
The differences found were statistically insignificant [18].
There are numerous controversies in the literature 
about the role of WBRT as a treatment adjuvant to SRS [8, 
35, 45–48, 54–56]. In retrospective studies Sneed et al. and 
Hu et al. did not find any positive effect of adjuvant WBRT 
on survival [54–56]. In three controlled clinical studies, the 
efficiency of SRS versus SRS + WBRT was evaluated [45]. 
Studies by Aoyama et al. [47] and Kochera et al. [46] did 
not show any difference in patients’ survival, but addition 
of WBRT statistically significantly improved local and dis-
tant (brain areas outside the SRS volume) control. The ef-
fectiveness of WBRT combined with an SRS boost used in 
the treatment of 1–3 brain metastases was compared with 
that of WBRT alone [35, 45, 51–53]. In a study of Andrews 
et al. (RTOG 9508), in a group of patients with single, inop-
erable brain metastasis, statistically significant improve-
ment of median survival was achieved, from 4.9 to 6.9 
months, after combined treatment with WBRT + SRS. In 
patients with 2 or 3 metastases, only improvement of local 
control was observed. Local control improvement, without 
overall survival improvement after WBRT + SRS treatment, 
was also found by Sanghavi et al. [50], Stafiński et al. [52] 
and Patil et al. in a meta-analysis presented in 2013 [53].
Many authors have reported the feasibility and efficacy 
of repeated SRS, as a salvage therapy, in the treatment of 
local recurrences of BMF-NSCLC after previous irradiation, 
in a highly selected group of patients [17, 35, 44, 58, 60, 61].
To conclude, SRS alone may be used in selected pa-
tients with single BMF-NSCLC, without neurological symp-
toms, having a good performance status (KPS – 90–100), 
with controlled extracranial disease. These patients need 
regular follow-up with frequent visits, as according to 
the literature 20–50% of them develop new BMF-NSCLC 
in regions outside the SRS volume, and they sometimes 
experience local recurrences that are amenable to further 
treatment (e.g. repeated radiotherapy or surgery) [8, 28, 
30, 62]. Literature data show clearly that WBRT following 
SRS reduces the risk both of local relapse and of develop-
ment of metastases in parts of the brain outside the SRS 
volume. In patients with single metastasis, addition of SRS 
to initial WBRT improves patients’ survival, and in patients 
with multiple metastases it improves local control without 
any effect on survival.
Whole brain radiotherapy
For several decades, WBRT combined with corticoste-
roid treatment has been a basic method of treatment of 
patients with BM-NSCLC. Whole brain radiotherapy alone 
is indicated primarily in patients:
•	 with multiple BM-NSCLC,
•	 not qualifying for surgery or SRS,
•	 with poor performance status,
•	 with uncontrolled extracranial disease.
Whole brain radiotherapy is also used as an adjuvant to 
surgery, and similarly as in the case of combination with 
SRS it allows for reduction of the number of brain metas-
tasis relapses [1, 4, 15, 19, 29, 30, 35–37].
Radiotherapy doses used in WBRT range from 20 to 
40 Gy, given in 5–20 fractions; the most common is the 
regimen administering 30 Gy in 10 fractions, and the ma-
jority of authors avoid administration of fraction doses 
higher than 3 Gy [30, 33, 35]. Levy et al. suggest a possi-
bility of improvement of WBRT efficacy, in patients with 
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single BMF-NSCLC, disqualified from surgery or SRS, by es-
calation of the dose to the metastatic lesion with photons 
from a linear accelerator [34].
Whole brain radiotherapy has a modest effect on sur-
vival of patients with BMF-NSCLC; median survival after 
this treatment ranges from 3 to 6 months [4, 5, 19, 28, 30, 
63], and half of patients die due to progression of brain 
metastases [30]. 47–56% of patients respond to the treat-
ment [4, 30, 35]. However, WBRT allows for: reduction of 
the dose of corticosteroids, improvement of neurological 
symptoms, improvement of quality of life, and survival 
prolongation in comparison to corticosteroid treatment 
alone [4, 19].
Whole brain radiotherapy vs. best supportive care
There is no doubt that there is a group of patients with 
BMF-NSCLC who do not benefit from WBRT and should 
receive only best supportive care (BSC); however, precise 
selection of these patients remains difficult [5, 64–66]. In 
a prospective study by Bezjak et al., 55% of patients with 
brain metastases had obvious progression or died during 
the first month after WBRT [64].
In a retrospective study conducted by Sundaresan et 
al. (2010), 23% of analysed patients with brain metasta-
ses from lung cancer died during the first 6 weeks [65]; 
the authors tried to develop a prognostic index for these 
patients with multiple brain metastases that would allow 
for selection of patients who would not benefit from WBRT 
because of a too short life expectancy. ECOG (Eastern Co-
operative Oncology Group) performance status was the 
sole statistically significant prognostic factor.
In 2012, Craighead and Chan defined benefit from 
WBRT as survival of over 3 months after diagnosis of brain 
metastases [63]. The results of their study suggest that 
patients from category 2 and 3 according to RPA-RTOG (re-
cursive partitioning analysis – Radiation Therapy Oncology 
Group) [67], with more than 3 metastases, do not benefit 
from WBRT, due to a short life expectancy (median survival 
3.9 and 2.8 months, respectively) [63]. RPA-RTOG criteria 
are presented in Table 2, and RECIST 1.1 (Response Evalua-
tion Criteria in Solid Tumours) response criteria for primary 
and metastases of the brain are presented in Table 3.
In 2013, Windsor et al. presented a group of 3459 pa-
tients subject to WBRT due to brain metastases from vari-
ous cancers [5]. After WBRT, 312 (17%) out of 1800 patients 
with lung cancer survived 6 months or less, and 1498 
(83%) survived more than 6 months. The results showed 
that older patients (median age – 64 vs. 61 years) and 
patients with a shorter interval between lung cancer di-
agnosis and WBRT (31 vs. 35 weeks) had worse survival; 
these differences were statistically significant. Concluding 
their study, definition of the group of patients for whom 
BSC is a better solution remains a challenge for investi-
gators. In 2013, preliminary results of a controlled clinical 
study of the Medical Research Council, QUARTZ, were pub-
lished. The study compared the results of WBRT with BSC 
in patients with BMF-NSCLC; 85% of patients in the WBRT 
group and 99% in the BSC group were in category 2 and 
3 according to RPA-RTOG criteria. Preliminary results of 
this study showed that using BSC alone did not worsen 
patients’ survival or their quality of life (median survival 
1.6 vs. 1.7 months) [68]. In the same year (2013) a study 
by Nieder et al. was published, which was similar to the 
QUARTZ study. In 41 patients BSC alone was used, in 
41 WBRT with a dose of 30 Gy/10 fr., and in 31 WBRT with 
a dose of 20 Gy/5 fr.; median survival of all patients was 
2.0 months, and in the groups listed above it was 1.7, 
2.2 and 2.2 months respectively; the authors confirm 
in general the conclusions of the QUARTZ study [33].
Whole brain radiotherapy complications
Tolerance of WBRT is usually good, and early reactions 
are usually mild and resolve within several weeks after 
irradiation; they include mainly headache, fatigue, nau-
sea and hair loss. Other early complications (≤ 6 months), 
in the form of a syndrome including somnolence, short-last-
ing memory disturbances and mild leukoencephalopathy, 
are also transient in nature. However, a serious problem 
Table 2. RPA-RTOG criteria
Prognostic factors Class I Class II Class III
Age (< 65 vs. > 65 years) All good prognostic 
factors
Other patients KPS < 70
Performance status (KPS < 70 vs. ≥ 70)
Extracranial metastases (yes vs. no)
Controlled primary (yes vs. no)
Table 3. RECIST 1.1 (Response Evaluation Criteria in Solid Tumours) – response criteria for primary and metastases of brain
RECIST 1.1. Response criteria for target lesions
Complete response (CR) Disappearance of all target lesions
Partial response (PR) At least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum 
diameters
Progressive disease (PD) At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on 
study and at least 5 mm increase or the appearance of one or more new lesions 
Stable disease (SD) Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the 
smallest sum diameters while on study
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is late complications (> 6 months after radiotherapy) that 
are in general irreversible, usually progressive and even 
life-threatening. The risk of developing the most serious 
of them, i.e. radiation-induced necrosis, is lower than 1% 
with appropriately dosed WBRT; encephalopathy occurs in 
2–18% of patients, usually after 2 years following radio-
therapy. Demyelination lesions and vascular damage may 
lead to memory, concentration and attention disturbanc-
es, mood swings, neurocognitive function (NCF) disorders 
and even dementia [19, 29, 35, 69]. It should be however 
kept in mind that many of these complications may be re-
lated to causes other than WBRT, e.g. disease progression, 
previous treatment (surgery, systemic treatment), anticon-
vulsants, patient’s age, concomitant diseases (atheroscle-
rosis, diabetes), etc. [19, 29, 35]. Prevention of late WBRT 
complications includes mainly: avoidance of exceeding 
fraction doses of 3 Gy, hippocampal sparing radiotherapy, 
and use of neuroprotective agents (memantine, donepezil, 
lithium, renin-angiotensin system blockers, etc.) [19].
To conclude, WBRT, due to its efficacy and lack of good 
alternative treatment options, remains a basic treatment 
for patients with multiple BMF-NSCLC and poor perfor-
mance status.
Summary
In summary, surgical treatment is recommended in pa-
tients with single BMF-NSCLC, with good performance sta-
tus (KPS of 70 or more) and controlled extracranial disease. 
Patients with single (1–3) BMF-NSCLC of diameter below 
33.5 cm, with no or only minor neurological symptoms, lo-
cated in different regions of the brain, including those not 
accessible to metastasectomy, with controlled extracranial 
disease, are the best candidates for SRS. Whole brain ra-
diotherapy following SRS reduces the risk of local relapse 
and progression of brain metastases outside the SRS vol-
ume. Whole brain radiotherapy alone, due to its efficacy 
and lack of good alternative treatment options, remains 
a basic treatment for patients with multiple BMF-NSCLC, 
poor performance status, with uncontrolled extracranial 
disease, disqualified from surgery or SRS.
The authors declare no conflict of interest.
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